- The report tracks the recent performance of the IPO market, including the Sci-Tech Innovation Board, the Growth Enterprise Market, and the Main Board, assuming all stocks are hit and sold at the market average price on the first day of listing, ignoring the lock-up period restrictions [2][10] - The report calculates the IPO yield for different account sizes, with A-class 2 billion scale accounts yielding 1.89%, B-class 2 billion scale accounts yielding 1.69%, A-class 10 billion scale accounts yielding 0.60%, and B-class 10 billion scale accounts yielding 0.55% [2][10] - The report tracks the median number of valid quotation accounts for recent 20 new stocks, with A-class valid quotation accounts for Sci-Tech Innovation Board stocks around 3062, B-class around 1602; A-class valid quotation accounts for Growth Enterprise Market stocks around 3591, B-class around 2079; A-class valid quotation accounts for Main Board stocks around 3790, B-class around 2275 [2][22] - The report lists the recent IPO results, including the issuance price, issuance P/E ratio, industry P/E ratio, number of new shares issued, actual fundraising amount, strategic placement, online issuance, offline issuance, online winning rate, online issuance oversubscription multiple, offline preliminary inquiry oversubscription multiple, offline subscription allocation ratio, and offline issuance effective subscription multiple [24] - The report calculates the theoretical IPO yield for different account sizes, assuming all stocks are hit, sold at the market average price on the first day of listing, and using 90% capital efficiency [39][40] - The report lists the monthly IPO yield and IPO yield rate for different account sizes, assuming all stocks are hit, sold at the market average price on the first day of listing, and using 90% capital efficiency [43][44][45][46] - The report lists the monthly IPO yield and IPO yield rate for different account sizes, assuming all stocks are hit, sold at the market average price on the first day of listing, and using 90% capital efficiency [47][50][51][52][53] - A-class 2 billion scale accounts IPO yield rate is 1.89% [10] - B-class 2 billion scale accounts IPO yield rate is 1.69% [10] - A-class 10 billion scale accounts IPO yield rate is 0.60% [10] - B-class 10 billion scale accounts IPO yield rate is 0.55% [10] - Sci-Tech Innovation Board stocks first-day average increase is 218.45% [16] - Growth Enterprise Market stocks first-day average increase is 227.38% [16] - Sci-Tech Innovation Board stocks A-class valid quotation accounts around 3062 [22] - Sci-Tech Innovation Board stocks B-class valid quotation accounts around 1602 [22] - Growth Enterprise Market stocks A-class valid quotation accounts around 3591 [22] - Growth Enterprise Market stocks B-class valid quotation accounts around 2079 [22] - Main Board stocks A-class valid quotation accounts around 3790 [22] - Main Board stocks B-class valid quotation accounts around 2275 [22] - The highest first-day increase for new stocks is 426.31% [33] - The highest fundraising amount for new stocks is 181.71 billion yuan [33] - The highest full subscription yield for new stocks is 141.4 million yuan [37] - The highest monthly IPO yield for A-class accounts is 248.20 million yuan [44] - The highest monthly IPO yield rate for A-class accounts is 6.22% [44] - The highest monthly IPO yield for B-class accounts is 179.55 million yuan [50] - The highest monthly IPO yield rate for B-class accounts is 5.04% [50]

IPO Pipeline Overview - As of July 27, there are 305 companies in the IPO pipeline, with 30 on the Shanghai Main Board, 36 on the Sci-Tech Innovation Board, 26 on the Shenzhen Main Board, 30 on the Growth Enterprise Market, and 183 on the Beijing Stock Exchange [2] - The total number of companies at various stages includes 24 accepted, 223 under inquiry, 12 approved, 27 suspended, and 19 registered [3] Newly Listed Companies - During the period from July 21 to July 27, two companies were newly listed: Shandong Shanda Electric Power Technology Co., Ltd. on the Growth Enterprise Market and Jiyuan Group Co., Ltd. on the Shanghai Main Board [4] - Shandong Shanda Electric Power Technology Co., Ltd. closed at 66.85 CNY per share, with a surge of 356.00% and a trading volume of 22.22 billion CNY, achieving a turnover rate of 82.61% [4][6] - Jiyuan Group Co., Ltd. closed at 40.75 CNY per share, with an increase of 274.54% and a trading volume of 13.72 billion CNY, achieving a turnover rate of 80.75% [6] New Counseling Record Companies - Six companies were newly recorded for counseling from July 21 to July 27, including Guangde Tianyun New Technology Co., Ltd. and Beijing Yingshirui Technology Co., Ltd. [7] - Guangde Tianyun New Technology Co., Ltd. focuses on the development, production, and sales of automotive sunroofs and interior components [8] - Beijing Yingshirui Technology Co., Ltd. integrates advanced cloud computing and AI technologies to provide digital service solutions for environmental monitoring [8] CSRC Review Status - Qingdao Taikaiying Special Tire Co., Ltd. successfully passed the review, while Xiamen Hengkang New Materials Technology Co., Ltd. was postponed [10] - Qingdao Taikaiying specializes in the design, research, sales, and service of tires for the mining and construction industries [12] CSRC Registration Approval - Three companies received registration approval from July 21 to July 27: Ningbo Nengzhiguang New Materials Technology Co., Ltd., Shanghai Balanshi Automotive Testing Equipment Co., Ltd., and Beijing Haochuang Ruitong Electric Equipment Co., Ltd. [14] - Ningbo Nengzhiguang focuses on the research, production, and sales of polymer additives and functional polymer materials [16] - Shanghai Balanshi specializes in automotive maintenance and testing equipment [17] Termination of Review - No companies withdrew from the review process during the period from July 21 to July 27 [20]

AI and Market Trends - AI applications are entering a rapid growth phase, supported by mature infrastructure and decreasing costs of large model calls, enhancing commercial potential[3] - China possesses significant data reserves and a broad demand scale, providing a competitive advantage for AI development[3] Market Performance - The A-share market experienced a general rise, with the Shanghai Composite Index up by 1.67% and the Shenzhen Component Index up by 2.33% during the week[15] - Mid-cap indices such as the CSI 500 and CSI 1000 outperformed large-cap indices, with increases of 3.28% and 2.38% respectively[17] Dietary Supplements Industry - The global dietary supplement market is projected to reach $223 billion by 2026, driven by population growth and increasing health awareness[5] - HMB, a key nutrient for muscle health, is expected to see global production reach 3,572 tons by 2030, indicating strong market potential[5] Investment Recommendations - Recommended stocks include Toris (拓尔思), which has a robust open-source intelligence data resource, and Songlin Technology (松霖科技), focusing on health robots[3] - Other notable mentions are Rongxin Culture (荣信文化), which is expanding into AI+ education scenarios[3] Corporate Actions - This week, two companies listed on the A-share market, with C Shanda and C Jiyuan seeing first-day gains of 356% and 274% respectively[33] - There were six new public offerings announced, with an average discount rate of 18.9% and an average return of 40.7% on recent fundraising projects[34][40]

Core Viewpoint - The article provides an overview of the latest trends in investment and financing activities in the domestic market, highlighting key sectors, regional distributions, and significant financing events. Group 1: Investment Overview - This week, there were 89 disclosed financing events in the domestic primary market, a decrease of 37 events compared to the previous week. The total disclosed financing amount was 7.181 billion RMB, with an average financing amount of 189 million RMB [5]. - The most active sectors in terms of financing events were smart manufacturing (22 events), healthcare (16 events), and artificial intelligence (16 events) [7]. Group 2: Sector Analysis - In terms of disclosed financing amounts, the artificial intelligence sector led with a total financing scale of approximately 2.480 billion RMB. Notably, "Zhongqing Robot," a developer of general-purpose humanoid robots, completed nearly 1 billion RMB in Series A financing [8]. - The healthcare sector followed with a disclosed financing total of 2.069 billion RMB. "Tongxin Medical," a developer of artificial heart assist devices, completed a financing round exceeding 100 million USD [9]. Group 3: Regional Distribution - The disclosed financing events were primarily concentrated in Shanghai (19 events), Jiangsu (18 events), and Beijing (12 events) [13]. Group 4: Stage Distribution - The stage distribution of the disclosed financing events included 64 early-stage, 19 growth-stage, and 6 late-stage events [16]. Group 5: Major Financing Events - The article highlights significant financing events, including the acquisition of a 23.4% stake in "Zhongying Electronics," a single-chip integrated circuit design developer, by "Zhineng Electronics" for 1.245 billion RMB [37].

Market Overview - As of July 25, the Shanghai Composite Index closed at 3593.66 points, down 12.07 points, a decrease of 0.33% [1] - The Shenzhen Component Index closed at 11168.14 points, down 24.92 points, a decrease of 0.22% [1] - The ChiNext Index closed at 2340.06 points, down 5.31 points, a decrease of 0.23% [1] Trading Activity - A total of 89 A-shares had a turnover rate exceeding 20% on this day [1] - Notable stocks with high turnover rates included: - C Jiyuan with a turnover rate of 54.05% and a closing price of 39.11 yuan, up 1.14% [1] - Nanfang Luji with a turnover rate of 53.88% and a closing price of 37.47 yuan, down 1.99% [1] - C Shanda with a turnover rate of 46.70% and a closing price of 56.34 yuan, down 7.32% [1] - Xizang Tianlu with a turnover rate of 45.81% and a closing price of 15.43 yuan, up 9.98% [1] Notable Stocks - Other stocks with significant turnover rates included: - Kangzhi Pharmaceutical with a turnover rate of 43.46% and a closing price of 7.61 yuan, up 0.66% [1] - Tianrun Technology with a turnover rate of 42.98% and a closing price of 32.76 yuan, up 30.00% [1] - Tietuo Machinery with a turnover rate of 40.09% and a closing price of 30.45 yuan, up 5.58% [1] - Stocks with notable declines included: - Shenong Agriculture with a turnover rate of 39.57% and a closing price of 4.94 yuan, down 9.69% [1] - Han Jian Heshan with a turnover rate of 38.93% and a closing price of 5.95 yuan, down 9.98% [1]

Core Insights - The company has over 20 years of experience in the global dietary supplement industry, focusing on scientific research and clinical trials to provide innovative and customized nutritional ingredients and formulations [1] - In 2024, the company achieved a revenue of 1.002 billion yuan, representing a year-on-year growth of 12.33% [1] Industry Overview - The global dietary supplement market exceeded $187 billion in 2023 and is expected to maintain a steady growth rate of 6% over the next three years, reaching $223 billion by 2026 [2] - The company operates as both a nutritional ingredient supplier and a formulation manufacturer, with strong competitiveness in HMB, glucosamine, and other nutritional ingredients [2] Product Segmentation - **HMB**: The company holds over 50% of the global market share and is a key player in the HMB industry, collaborating with major companies like Metabolic and Abbott to drive HMB commercialization [2] - **Glucosamine**: The company is a leading provider of high-quality glucosamine, achieving a stable global market share of 12.61% in 2024 [3] - **Other Nutritional Ingredients**: The company has enhanced its research capabilities through the strategic acquisition of Metabolic Technologies, focusing on new ingredient development [3] - **Formulation Business**: The company emphasizes innovative dosage forms and has obtained TGA GMP certification for its production facility, enabling it to offer personalized nutritional solutions [4] Financial Projections - The company is expected to achieve revenues of 1.184 billion yuan, 1.436 billion yuan, and 1.758 billion yuan from 2025 to 2027, with year-on-year growth rates of 18.2%, 21.2%, and 22.5% respectively [5] - Projected net profits for the same period are 199 million yuan, 239 million yuan, and 310 million yuan, with growth rates of 13.8%, 20.1%, and 30.1% respectively [5]

Group 1 - C Jiyuan (603262) saw a first-day increase of 274.54%, with a turnover rate of 80.75% and a transaction amount of 1.372 billion yuan [2] - The stock had a net inflow of 337 million yuan from major funds on its first trading day, with a net inflow of 123 million yuan from large orders and 215 million yuan from big orders [3] - The stock's first-day financing amount was 55.2954 million yuan, accounting for 4.03% of the total trading volume, with a latest financing balance of 51.4479 million yuan, representing 3.25% of the circulating market value [2][3] Group 2 - The company primarily engages in the research and development of dietary nutritional supplements and their industrialization [3] - On the first trading day, the top five trading departments on the dragon and tiger list had a total transaction amount of 195 million yuan, with a net purchase of 10.0034 million yuan [3]

Group 1 - The core viewpoint of the article is that Jiyuan Group has successfully listed on the Shanghai Stock Exchange, with a significant opening increase of 368.75% and a closing price of 40.75 yuan per share [1] - Jiyuan Group specializes in the research, innovation, and industrialization of dietary nutritional supplements, being the largest global supplier of HMB raw materials and a core supplier of high-quality glucosamine and formulations [1] - The company has a comprehensive industry chain capability, covering everything from nutrient molecular screening and evaluation, efficacy research, functional claims, patent applications, market access and promotion, to raw material production and finished product processing [1] Group 2 - Jiyuan Group's founder and chairman, Zhou Jingshi, highlighted the company's commitment to continuous innovation and global development over the past 20 years, holding 228 domestic and international invention patents [1] - The company serves over 800 clients globally, benefiting from the expanding applications of HMB in sports nutrition and health for the elderly, leading to steady performance growth [1] - The net profits for Jiyuan Group are projected to be 144 million yuan, 161 million yuan, and 175 million yuan for the years 2022, 2023, and 2024 respectively [1] Group 3 - Looking ahead, Jiyuan Group plans to accelerate its global layout by establishing production capacities in Hong Kong, Thailand, the United States, and Europe, aiming to enhance its competitive advantages in nutritional raw materials and personalized nutrition [2] - The company aims to promote "Made in China" dietary nutritional supplements on the global market, leveraging nutrition to improve overall human health [2]

具体来看，今日上榜的营业部中，共有5家机构专用席位现身，即卖一、卖二、卖三、卖四、卖五，合 计净卖出9260.73万元。 资金流向方面，今日该股主力资金净流入3.37亿元，其中，特大单净流入1.23亿元，大单资金净流入 2.15亿元。近5日主力资金净流入3.37亿元。 7月4日公司发布的一季报数据显示，一季度公司共实现营业收入2.65亿元，同比增长16.59%，实现净利 润4260.17万元，同比增长9.25%。 7月22日公司发布上半年业绩预告，预计实现净利润1.02亿元至1.12亿元，同比变动区间为 8.56%~19.20%。（数据宝） C技源7月23日交易公开信息 C技源(603262)今日上涨274.54%，全天换手率80.75%，成交额13.72亿元，振幅27.93%。龙虎榜数据显 示，机构净卖出9260.73万元，营业部席位合计净买入1.03亿元。 上交所公开信息显示，当日该股因无价格涨跌幅限制上榜，机构专用席位净卖出9260.73万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.95亿元，其中，买入成交额为1.03亿 元，卖出成交额为9260.73万元，合计净买入1000.34 ...

Core Viewpoint - TSI Group Co., Ltd. (referred to as "TSI Group") successfully listed on the Shanghai Stock Exchange, with a closing price of 40.75 yuan, representing a significant increase of 274.54% and a total market capitalization of 16.3 billion yuan [1] Company Overview - TSI Group specializes in the research, innovation, and industrialization of dietary nutritional supplements, positioning itself as an international enterprise group [1] - Prior to the issuance, TSI Hong Kong held 27,567.38 million shares, accounting for 78.76% of the total share capital, and remains the controlling shareholder post-issuance with a reduced stake of 68.92% [1] Shareholding Structure - The actual controllers, Zhou Jingshi and Long Ling, held 58.91% and 62.82% of TSI Group and TSI Holdings respectively, controlling a total of 84.47% voting rights before the issuance [2] - Post-issuance, the couple controls 73.91% of the voting rights, maintaining their status as actual controllers [2] Financial Performance - In 2022, 2023, and 2024, the company's operating revenues were 947.24 million yuan, 891.89 million yuan, and 1 billion yuan respectively, with net profits of 143.61 million yuan, 160.51 million yuan, and 175.34 million yuan [5] - The total assets as of December 31 for 2022, 2023, and 2024 were 924.46 million yuan, 1.02 billion yuan, and 1.19 billion yuan respectively, with a decreasing debt ratio from 34.30% to 20.23% [6] Fundraising and Project Allocation - The total number of shares issued was 50.01 million at a price of 10.88 yuan per share, raising a total of 54.41 million yuan, with a net amount of 47.98 million yuan after expenses [3] - The planned allocation of raised funds includes projects for the construction of a nutritional health raw material production base, expansion of production lines, and a technology innovation center, totaling 602.73 million yuan [4] Customer Dependency - TSI Group is the preferred supplier of HMB nutritional raw materials for Abbott Group, with sales to Abbott accounting for 23.44%, 17.38%, and 19.44% of the main business income in the reporting periods [10]